The yeast Candida albicans occurs in most healthy people as a harmless colonizer in the digestive tract. However, it can also cause life-threatening infections, especially in immunocompromised patients.
These infections are usually treated with the drug fluconazole, which inhibits the synthesis of ergosterol in Candida. Ergosterol fulfils similar important functions in fungi as cholesterol in humans.
Candida albicans can, however, become resistant to this drug. Scientists have uncovered the main mechanisms of fluconazole resistance in recent years. The group of Professor Joachim Morschhäuser from the Institute for Molecular Infection Biology at Julius-Maximilians-Universität Würzburg (JMU) in Bavaria, Germany, has contributed important findings.
The fungus succeeds in becoming resistant with numerous mechanisms. For example, it uses pumps to transport the drug out of its cells. “Highly resistant Candida albicans, in which fluconazole therapy fails, usually use a combination of several of these mechanisms,” says Morschhäuser.
New combinations of resistance mechanisms
Normally Candida albicans reproduces asexually by cell division. Morschhäuser’s research group has now discovered that resistant fungal cells can quickly switch to sexual reproduction in the presence of fluconazole. In this case, the cells fuse and unite their genetic material. In the offspring cells, different resistance mechanisms are newly combined and the fungal population thus becomes even less sensitive to fluconazole.
“In our investigations, we found out that the cells that retained the advantageous resistance characteristics are selected and become dominant in the population when treated with fluconazole,” says first author Christina Popp. Fluconazole not only selects for resistance mutations, but can also lead to changes in the genome that make the normally asexual fungus “mating-competent,” thereby enabling the cells to combine individually acquired resistance mechanisms and produce highly resistant offspring.
Knowledge about the molecular mechanisms of drug resistance can be useful for the development of better and new drugs and help overcome resistance.
Morschhäuser assumes that the resistance mechanisms described here are only one example of how Candida albicans can change in its host. Next, his team wants to investigate whether other forms of adaptation can also contribute in a similar way to the successful establishment of the fungus in different host niches.
Clues to the innate drug resistance of a cocoa-fermenting pathogen
Christina Popp et al. Evolution of Fluconazole-Resistant Candida albicans Strains by Drug-Induced Mating Competence and Parasexual Recombination, mBio (2019). DOI: 10.1128/mBio.02740-18
Quick Take: Antibiotic management of urinary tract infection in elderly patients in primary care and its association with bloodstream infections and all-cause mortality
Urinary tract infection (UTI) is the most common bacterial infection in elderly patients, and the spectrum of illness ranges from...
Quick Take: Duration of antibiotic treatment for common infections in English primary care: cross sectional analysis and comparison with guidelines
Antibiotic resistance is a growing challenge across the globe. As such, there have been increasing efforts towards reducing unnecessary or...
Quick Take: Association of Systemic Antibiotic Treatment of Acne With Skin Microbiota Characteristics
Systemic antibiotics are commonly used in the treatment of acne. However, the impact of their use on the complete bacterial...
New herpes zoster vaccine predicted to be more cost effective than predecessor
1. In a computational model, the new “recombinant zoster vaccine” (RZV) was predicted to be most cost-effective than the previous...
The focus areas of Annual Review Meeting: ◽️HSTP-II ◽️Health Extension & Health Development Army program Study ◽️Woreda Transformation plan ◽️Mental Health ◽️#NCDs particularly Hypertension ◽️Immunization ◽️Nutrition ◽️I-CARE ◽️#TB & #NTDs ◽️Essentail Health Service Package twitter.com/amirabiy/statu…
The 21st Health Sector Annual Review Meeting will be held in Addis Ababa from October 15-18, 2019. Field visits, side events, and a variety of crucial discussions are part of the event.— Amir Aman, MD (@amirabiy) October 12, 2019
It will be live streamed on the MoH social media accounts. Join us online and give comments. pic.twitter.com/BA008jcrcq